1
项与 CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) 相关的临床试验Professor of Medicine Second Hospital of Shandong University
The investigators developed a dual-target CAR-T targeting CD38 and CS1. Previous experimental results showed that the investigators double-target CAR-T not only had a good killing effect on CD38/CS1 double-positive tumor cells, but also had a high killing rate on CD38 or CS1 single-positive tumor cells. The investigators further study also found that the killing rate of the investigators dual-target CAR-T after mixing CD38 and CS1 monoyang tumor cells was over 80%. The advantage of the investigators dual-target CAR-T product is that the killing effect on single-yang, double-yang and single-yang mixed tumors is stable, and the killing rate is above 80% (see Figure 1). It has a wide killing range and can effectively reduce the phenomenon of tumor immune escape. Therefore, the investigators dual CAR products have good advantages and development potential.
100 项与 CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) 相关的临床结果
100 项与 CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) 相关的转化医学
100 项与 CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) 相关的专利(医药)
100 项与 CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) 相关的药物交易